Abstract
Parkinson´s disease (PD) is a common neurodegenerative movement disorder and leucine-rich repeat kinase 2 (LRRK2) is a promising therapeutic target for disease intervention. However, the ability to stratify patients who will benefit from such treatment modalities based on shared etiology is critical for the success of disease-modifying therapies. Ciliary and centrosomal alterations are commonly associated with pathogenic LRRK2 kinase activity and can be detected in many cell types. We previously found centrosomal deficits in immortalized lymphocytes from G2019S-LRRK2 PD patients. Here, to investigate whether such deficits may serve as a potential blood biomarker for PD which is susceptible to LRKK2 inhibitor treatment, we characterized patient-derived cells from distinct PD cohorts. We report centrosomal alterations in peripheral cells from a subset of early-stage idiopathic PD patients which is mitigated by LRRK2 kinase inhibition, supporting a role for aberrant LRRK2 activity in idiopathic PD. Centrosomal defects are detected in R1441G-LRRK2 and G2019S-LRRK2 PD patients and in non-manifesting LRRK2 mutation carriers, indicating that they accumulate prior to a clinical PD diagnosis. They are present in immortalized cells as well as in primary lymphocytes from peripheral blood. These findings indicate that analysis of centrosomal defects as a blood-based patient stratification biomarker may help nominate idiopathic PD patients who will benefit from LRRK2-related therapeutics.
Similar content being viewed by others
Introduction
Parkinson’s disease (PD) is characterized by the progressive loss of dopaminergic neurons in the substantia nigra which results in motor symptoms such as tremor, rigidity, bradykinesia, and postural instability. At the time of clinical diagnosis, a large percentage of these neurons have already degenerated1. Whilst current therapies can temporarily improve motor symptoms, there are no treatments which slow or halt the disease. PD patients display differences in clinical symptoms and rates of disease progression which may reflect distinct underlying molecular and biological alterations2,3. Hence, identifying biomarkers for the early diagnosis of at least some types of PD and for the assessment of therapeutic interventions has become a key challenge in the field.
Genetic variations in leucine-rich repeat kinase 2 (LRRK2) are strongly implicated in PD risk. Distinct missense mutations are a frequent cause of autosomal-dominant inherited PD, and common variants in the LRRK2 gene are associated with a greater risk of develo** idiopathic PD4,5,6,7,8. All known familial missense mutations increase the kinase activity of LRRK29,10. Increased kinase activity has also been detected in PD patients with certain other genetic forms of PD and in postmortem brain tissue from at least some idiopathic PD patients11,12,13. These findings indicate that increased LRRK2 activity may be implicated in a significant portion of PD cases.
LRRK2 is highly expressed in peripheral immune cells as compared to central nervous system14, suggesting that blood-based assays may allow for the identification of PD patients who share pathogenic mechanisms due to elevated LRRK2 activity. Increased LRRK2 kinase activity results in enhanced autophosphorylation and phosphorylation of substrates including Rab GTPases which act as master regulators of intracellular trafficking events9,15,16,17. Therefore, expression or phosphorylation levels of LRRK2 and its Rab substrates have the potential to serve as biomarkers for PD due to increased LRRK2 activity18. However, extensive studies in blood-derived cells employing distinct approaches to detect levels/phosphorylation of LRRK2 or Rab substrates have been relatively unsuccessful in differentiating LRRK2 mutation PD patients or idiopathic PD patients from healthy controls18,19,20,21,22,23,24,25,26,27,28.
Cellular consequences downstream of enhanced LRRK2 kinase activity such as lysosomal dysfunction29, which can lead to lysosomal exocytosis, may comprise alternative LRRK2 biomarkers. Lysobisphosphatidic acid (also called BMP [bis(monoacylglycerol)phosphate]), a phospholipid in late endosomes/lysosomes, is increased in urine in G2019S-LRRK2 PD cases compared to healthy controls and is currently employed as a biomarker in clinical trials with LRRK2 kinase inhibitors30,31,32. Similarly, increased LRRK2 autophosphorylation and Rab substrate phosphorylation can be detected in urinary exosomes from LRRK2 mutation PD patients33,34,35,36,37, but none of these urinary measures reliably stratify idiopathic PD patients who may benefit from LRRK2 inhibitor treatment approaches. Hence, there exists an unmet need for patient stratification biomarkers able to define not only LRRK2 variant carriers but also subgroups of idiopathic PD patients who share the same LRRK2 kinase-mediated deficits.
Rab10 is a prominent LRRK2 kinase substrate9,16. Phosphorylation of Rab10 impairs its normal function in membrane trafficking38,39, but allows it to interact with a new set of effector proteins including RILPL116. RILPL1 is localized at the mother centriole and recruits phosphorylated Rab10 to this location40,41. The mother centriole forms the base upon which cilia are formed, and the centriolar phospho-Rab10/RILPL1 complex blocks cilia formation in a variety of cell types in vitro16,40,42,43. Ciliogenesis deficits are also observed in certain neurons and astrocytes in pathogenic G2019S-LRRK2 or R1441C-LRRK2 knockin mouse models40,44, suggesting that they are a direct cellular consequence of pathogenic LRRK2 mutations and observable in the intact rodent brain.
The LRRK2-mediated centriolar phospho-Rab10/RILPL1 complex plays additional roles in non-ciliated cells. In interphase cells, the mother and daughter centriole associate to form a single centrosome in a process called centriole cohesion. Upon centriole duplication in S phase of the cell cycle, the two centrosomes are held together by a process called centrosome cohesion, and both centriole and centrosome cohesion are mediated by a common set of linker proteins45,46,47,48,49,50. We have previously shown that mutant LRRK2 causes centrosomal cohesion deficits which are dependent on the presence of RILPL1 and Rab10 in a variety of cell types in vitro42,43,51. Centrosomal cohesion deficits were further observed in immortalized lymphocytes (LCLs) from a cohort of G2019S-LRRK2 PD patients as compared to healthy controls, and were reverted by the LRRK2 kinase inhibitor MLi2 in all cases52. MLi2-sensitive cohesion deficits were also present in several early-stage idiopathic PD patients, suggesting the possibility that this cellular readout may help to stratify idiopathic PD patients susceptible to LRRK2-related therapeutics52.
Here, we present evidence that LRRK2 kinase activity-mediated cohesion deficits are common to distinct LRRK2 mutation carriers, detectable in a subset of idiopathic PD patients and present in peripheral blood-derived cells. Our data substantiate a role for increased LRRK2 kinase activity in at least some idiopathic PD patients and suggest that blood-based PD patient stratification according to cohesion deficits may hold promise in the context of clinical trials with LRRK2 inhibitors.
Results
Centrosomal cohesion deficits in a subset of idiopathic PD patient-derived cells are mitigated by LRRK2 kinase inhibition
We first determined whether centrosomal cohesion deficits can be observed in a larger sampling of idiopathic PD patients. For this purpose, we employed patient-derived Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCLs) from a cohort of PD patients (n = 35) and controls (n = 3) (Table 1). Centrosomes were only scored when positive for two distinct centrosomal markers (γ-tubulin and pericentrin), since the percentage of cells with duplicated centrosomes as determined by such an approach closely matches the percentage of cells in G2 phase as determined by flow cytometry52. In around 90% of cells from a healthy control LCL line, the distance between centrosomes was less than 1.3 μm. The remaining 10% of cells showed a separation of centrosomes by more than 1.3 μm, and these cells were considered as harboring split centrosomes52. When quantifying the distance between duplicated centrosomes in the different LCL lines, ten out of 35 PD LCLs displayed a centrosomal cohesion deficit which was similar to that in LCL lines from G2019S-LRRK2 PD patients52 (Fig. 1a–c). This deficit was reverted upon short-term incubation with the LRRK2 kinase inhibitor MLi2 in all cases (Fig. 1b–d). It was not associated with changes in the percentage of cells displaying two centrosomes (Fig. 1e), and did not correlate with sex or age at diagnosis (Table 1).
a Example of one healthy control and two PD LCL lines stained for two centrosomal markers (γ-tubulin and pericentrin) and DAPI. Arrows point to centrosomes co-stained with both markers. Scale bar, 10 μm. b The centrosome phenotype was quantified from 100–150 cells per line from 3 control and 35 PD lines. c In parallel experiments, the centrosome phenotype was quantified from 5 previously described control and 5 G2019S-LRRK2 PD lines52. Based on this comparison, idiopathic PD LCL lines were considered to have a cohesion deficit when displaying ≥20% splitting, with 10/35 lines (28%) found to display a centrosomal cohesion deficit reverted by MLi2 (50 nM, 2 h). Bars represent mean ± s.e.m.; control versus PD (split) (p = 0.001); PD (split) versus PD (split) + MLi2, (p < 0.001); ctrl versus G2019S-LRRK2 PD (p < 0.001); G2019S-LRRK2 PD versus G2019S-LRRK2 PD + MLi2 (p < 0.001). ***p < 0.005; ****p < 0.001. d Paired t-test analysis of centrosomal cohesion deficits from each cell line in the absence or presence of MLi2 as indicated. Note that differences in the values between 0 and 15% are not significant given the small number of cells displaying a duplicated split centrosome phenotype. e Quantification of the percent of cells displaying two centrosomes (positive for both pericentrin and γ-tubulin) from a total of 100–150 cells per LCL line.
Quantitative immunoblotting of extracts from the different idiopathic PD LCLs showed highly variable levels of total LRRK2, but no differences in the levels of LRRK2 between LCLs with or without a centrosomal cohesion deficit (Fig. 2a, b). Similarly, no differences were observed in the levels of pS935-LRRK2, pT73-Rab10 or total Rab10 amongst idiopathic PD LCLs with or without a cohesion deficit (Fig. 2b). Correlation analysis was performed to determine possible associations between LRRK2 and pT73-Rab10 levels across all samples. This analysis indicated a significant positive correlation between LRRK2 levels and pT73-Rab10 phosphorylation (Fig. 2c). Thus, and similar to what we previously reported for a different cohort of idiopathic PD LCLs52, LRRK2 kinase activity-mediated centrosomal cohesion deficits are detectable in a subset of idiopathic PD samples, even though they do not correlate with increased LRRK2 or pT73-Rab10 levels as assessed by quantitative Western blotting techniques.
a Example of two control and 12 PD LCL lines. Cells were lysed and extracts subjected to quantitative immunoblot analysis with the indicated antibodies and membranes were developed using Odyssey CLx scan Western Blot imaging system. pT73-Rab10 and total Rab10, as well as pS935-LRRK2 and total LRRK2 were multiplexed, and the same control line (S001) was run on every gel to compare samples run on different gels. b Immunoblots were quantified for LRRK2/tubulin, pS935/tubulin, pS935/LRRK2, Rab10/tubulin, pT73-Rab10/tubulin and pT73-Rab10/Rab10 as indicated, with no differences observed between PD LCL lines with or without a centrosome splitting phenotype. Bars represent mean ± s.e.m. c Spearman correlation analysis between levels of LRRK2/tubulin and pT73-Rab10/tubulin (top) or pS935/tubulin and pT73-Rab10/tubulin (bottom). A significant association is observed between LRRK2 or S935-LRRK2 levels and pT73-Rab10 levels in PD LCLs. Red datapoints indicate the ten PD samples which display a centrosomal cohesion deficit. Rho and p-values are indicated for each correlation analysis.
Lysosomal damage causes LRRK2 kinase-mediated increases in pT73-Rab10 levels in both control and idiopathic PD patient-derived cells
Recent studies have shown that treatment of cells with the lysosome membrane-rupturing agent L-leucyl-L-leucine methyl ester (LLOMe) causes recruitment and activation of LRRK2 at damaged lysosomes which is associated with a potent increase in pT73-Rab10 levels53,54,55. Consistent with these reports, LLOMe treatment caused a time-dependent increase in pT73-Rab10 levels which was reverted by MLi2 (Supplementary Fig. 1). This correlated with an MLi2-sensitive accumulation of pT73-Rab10 in vesicular structures near the centrosome which were positive for the endolysosomal marker LAMP1 (Supplementary Fig. 2) and with a cohesion deficit which was reverted by MLi2 (Supplementary Fig. 3). Moreover, the LLOMe-mediated alterations were observed in both healthy control and G2019S-LRRK2 LCLs (Supplementary Figs. 1–3). Hence, we reasoned that LLOMe-triggered LRRK2 activation may allow us to better detect potential differences in pT73-Rab10 levels amongst idiopathic PD LCL lines. Cells were treated with or without LLOMe and MLi2, and the LLOMe-induced increase in pT73-Rab10 levels was determined for each cell line. LLOMe treatment induced a similar increase in pT73-Rab10 levels in control LCLs and in idiopathic PD LCLs irrespective of whether they displayed a centrosomal cohesion phenotype (Fig. 3a, b). The LLOMe-induced increase in pT73-Rab10 levels was reduced upon MLi2 treatment in most cases (Fig. 3c, Supplementary Fig. 4). Interestingly though, some idiopathic PD LCLs did not display a LLOMe-induced increase in pT73-Rab10 levels (Fig. 3b). Such lack of LLOMe-mediated potentiation of pT73-Rab10 levels marginally correlated with high basal levels of pT73-Rab10 in the absence of LLOMe treatment (Fig. 3d), and further work is required to determine whether these idiopathic PD patient-derived cells already harbor lysosomal damage and thus display maximal LRRK2 kinase activity. In either case, these data show that neither basal nor LLOMe-induced pT73-Rab10 levels correlate with the MLi2-sensitive centrosomal cohesion deficits observed in a subset of idiopathic PD LCLs.
a Example of three PD LCL lines with or without treatment with LLOMe (1 mM) and MLi2 (50 nM) for 2 h as indicated. Cells were lysed and extracts subjected to multiplexed immunoblotting with the indicated antibodies. b The percentage of LLOMe-triggered increase in pT73-Rab10/Rab10 levels in the absence or presence of MLi2 was calculated for each LCL line. LLOMe triggers similar increases in pT73-Rab10/Rab10 levels in control and PD LCLs with or without a cohesion phenotype. Bars represent mean ± s.e.m.; ctrl versus ctrl + MLi2 (p = 0.004); PD (split) versus PD (split) + MLi2 (p = 0.006); PD (non-split) versus PD (non-split) + MLi2 (p < 0.001): ****p < 0.001; ***p < 0.005; **p < 0.01. c Paired t-test analysis of LLOMe-triggered increase in pT73-Rab10/Rab10 levels from each cell line in the absence or presence of MLi2. Note that the LLOMe-triggered increase in pT73-Rab10/Rab10 levels is reduced by MLi2 treatment in most cell lines. d Spearman correlation analysis between the percentage of LLOMe-triggered increase in pT73-Rab10/Rab10 levels versus basal pT73-Rab10/Rab10 levels in the absence of LLOMe treatment. There is a negative correlation between basal pT73-Rab10/Rab10 levels and the efficacy of the LLOMe-mediated increase in pT73-Rab10/Rab10 levels. Red datapoints indicate the ten PD samples which display a centrosomal cohesion deficit. Rho and p-values are indicated (in italics values without the two outliers).
Identification of gene variants in idiopathic PD samples
We next wondered whether the centrosomal cohesion deficits in the idiopathic PD LCLs may be due to genetic alterations in select genes impacting upon centrosomal cohesion in a LRRK2 kinase activity-mediated manner. Whole exome sequencing revealed single nucleotide variants (SNVs) in PD-relevant genes for some LCL lines (Supplementary Table 1). Amongst the idiopathic PD lines which displayed a centrosomal cohesion deficit, one line harbored a variant in the translational repressor GIGYF2, a gene at the PARK11 locus with an unconfirmed link to PD56,57. Amongst the PD lines without a cohesion deficit, one displayed a variant in ATP13A2, and two displayed a known pathogenic missense mutation in PRKN (Supplementary Table 1). Since heterozygous mutations in the GBA gene are the most frequent known genetic risk factor for PD, we additionally performed long-range PCR and Sanger sequencing of the GBA gene58, which allowed for identification of the E326K variant known to be associated with PD risk in two lines without a cohesion phenotype (Supplementary Table 1). Therefore, the MLi2-sensitive cohesion deficits observed in a subset of idiopathic PD samples are not due to mutations in LRRK2 or in other genes related to PD risk, raising the possibility that variants unrelated to disease risk may be mediating the phenotype.
Whole exome sequencing data were next analyzed to determine whether any other gene (or combination thereof) may be a better pharmacogenomic predictor than a PD gene mutation. Gene burden analyses indicated no significant burden of rare variants for any single gene after correcting for multiple comparisons (Supplementary Tables 2–4). The highest association between the centrosomal cohesion phenotype and rare variants was found within the TBC1D3D gene (Supplementary Table 3), a member of the TBC1D3 family which may act as an effector protein for Rab559 (p = 1.44 × 10−5). Another association was observed with rare variants in NOTCH2NLC (p = 0.00055851) (Supplementary Table 3), and repeat expansions in NOTCH2NLC have recently been detected in idiopathic PD cases60,61. Pathway analysis indicated a significant over-representation of a KEGG pathway (hsa04612: Antigen processing and presentation, FDR = 0.0032, enrichment ratio 27.71) (Supplementary Table 2), and the same gene list was also significantly enriched for a specific domain (PF06758: Repeat of unknown function (DUF1220), FDR = 1.14 e-07) and comprising the NBPF10, NBPF12, NBPF14, NBPF9 and PDE4DIP genes (Supplementary Table 3).
Interestingly, TBC1D3, NOTCH2NL and DUF1220 domain-containing genes are all hominoid-specific genes which have undergone duplications during evolution62,63. Expression of either TBC1D3, NOTCH2NL or DUF1220 protein domains drives proliferation of neural stem and progenitor cells and promotes cortical brain expansion and folding64,Peripheral blood mononuclear cell (PBMC) isolation and transformation For the San Sebastian cohort, 35 ml of patient-derived blood was subjected to immediate purification of PBMCs using BD Vacutainer (CPT) Sodium Heparin tubes, and purified PBMCs were frozen at high cell density (1 × 107 cells/tube) in cryopreservation medium (90% FBS, 10% DMSO). For all patients, 1–2 cryovials of purified PBMCs were employed to generate LCLs, and the remainder of cryovials was employed for direct analysis as described below. Lymphocytes were immortalized with Epstein-Barr virus (EBV) according to standard transformation protocols86 which include cell separation by gradient centrifugation and lymphocyte growth enhancement with 1% (v/v) of the mitogenic phytohemagglutinin-M (PHA-M, ThermoFisher 10576015). Samples (n = 10) collected through the LRRK2 Biobanking Initiative at Columbia University were used for assay development. PBMCs were collected from patients and control subjects at the Movement Disorder Division in the Department of Neurology at Columbia University Irving Medical Center. Participants were screened for the LRRK2 G2019S mutation as well as several GBA1 mutations and variants28. All participants provided written informed consent to take part in the study, and the study protocol was approved by the IRBs of both Columbia University (CUIMC). PBMCs were isolated using standard protocols as previously described87. Cells were resuspended in RPMI medium containing 40% FBS and 10% DMSO, counted, and aliquoted at 3 × 106 viable cells per cryovial. Frozen cells were stored at −80 °C. LCLs were grown as previously described52. Briefly, cells were maintained in RPMI 1640 medium (ThermoFisher, 21870076) supplemented with 20% fetal bovine serum (ThermoFisher, 10437028), 2% L-glutamine (ThermoFisher, 25030081), 20 units/ml penicillin and 20 μg/ml streptomycin (ThermoFisher, 15140122) in T75 flasks (ThermoFisher, 156499) in 5% CO2 at 37 °C. Cells were maintained at a density of 106 cells/ml, with cell density monitored every other day using trypan blue staining. Cell clumps were dispersed by pipetting, and 500´000 cells/ml treated in 1.5 ml tubes with DMSO or 50 nM MLi2 (Abcam, ab254528) for 2 h before processing for immunocytochemistry. HEK293T, murine embryonic fibroblast (MEF) and A549 cells were cultured as previously described42. LRRK2-IN1 (Tocris, 4273/10), GSK2578215A (Tocris, 4629/5), CZC25146 (MedChemExpress, HY-15800), GNE-0877 (MedChemExpress, HY-15796), GNE-7915 (MedChemExpress, HY-18163), PF-06447475 (MedChemExpress, HY-12477) and PF-360 (MedChemExpress, HY-120085) were added at the indicated concentrations for 2 h before processing for immunocytochemistry where indicated. Cryopreserved PBMCs were quickly thawed in a 37 °C waterbath, and transferred to 50 ml tubes containing 10 ml prelaid warm growth medium (RPMI 1640 medium with 20% fetal bovine serum, 2% L-glutamine, 20 units/ml penicillin and 20 μg/ml streptomycin), and cells centrifuged at 300 × g for 5 min at room temperature. The cell pellet was gently resuspended, and cells treated in growth medium in 12-well plates (1 × 106 cells/well) with either DMSO or MLi2 (200 nM) for 30 min before processing for immunocytochemistry as described below. Coverslips (13 mm diameter) were placed into 24-well plates and coated with Cell-Tak and Tissue Adhesive solution (Corning, 354240) according to manufacturer´s instructions. After 30 min incubation at 37 °C, the solution was removed and coverslips were rinsed twice with distilled water followed by air-drying. LCLs or PBMCs (500´000 cells/coverslip) were added to dry-coated coverslips and attached by slight centrifugation at 20 × g for 5 min at room temperature (without brake). LCLs and PBMCs were fixed with 2% paraformaldehyde (PFA) in PBS for 20 min at room temperature followed by 5 min of ice-cold methanol fixation (for γ-tubulin staining only). Upon fixation, cells were permeabilized with 0.2% Triton-X100/PBS for 10 min at room temperature and blocked for 1 h in 0.5% BSA (w/v) (Millipore, 126579) in 0.2% Triton-X100/PBS (blocking buffer). Coverslips were incubated with primary antibodies in blocking buffer at 4 °C overnight. The following day, coverslips were washed three times for 10 min in 0.2% Triton-X100/PBS, followed by incubation with secondary antibodies in 0.2% Triton-X100/PBS for 1 h at room temperature. Coverslips were washed three times in 0.2% Triton-X100/PBS, rinsed in PBS, air-dried, and mounted in mounting medium with DAPI (Vector Laboratories, H-1200). Primary antibodies included mouse monoclonal anti-γ-tubulin (1:1000, Abcam ab11316), mouse monoclonal anti-LAMP1 (1:500, Santa Cruz Biotechnology, sc-20011), rabbit polyclonal anti-pericentrin (1:1000, Abcam ab4448) and rabbit monoclonal anti-pT73-Rab10 (1:1000, Abcam ab241060). Secondary antibodies were all from Invitrogen, were employed at a 1:1000 dilution, and included Alexa488-conjugated goat anti-mouse (Invitrogen, A11001) or goat anti-rabbit (Invitrogen, A11008), Alexa568-conjugated goat anti-mouse (Invitrogen, A11004) or goat anti-rabbit (Invitrogen, A11011) and Alexa647-conjugated goat anti-rabbit (Invitrogen, A21244). For bromodeoxyuridine (BrdU) labeling of HEK293T, A549, and LCLs, cells were labeled with 10 μM BrdU (Abcam, ab142567) in respective full medium for 24 h, followed by fixation using 2%PFA/PBS for 20 min at room temperature. For PBMCs, cells were cultured in full medium for 48 h in either the presence or absence of PHA-M (1% v/v) with 10 μM BrdU for the last 24 h, followed by fixation as described above. In all cases, cells were washed with PBS for 10 min, permeabilized with 0.2% Triton-X100/PBS for 10 min at room temperature followed by DNA hydrolysis with 1 M HCl in PBS/0.2% Triton-X100 for 1 h at room temperature. Coverslips were rinsed three times with PBS and blocked for 1 h in 5% BSA (w/v) (Millipore, 126579) in 0.2% Triton-X100/PBS (blocking buffer). BrdU incorporation was detected by immunocytochemistry using an FITC-labeled BrdU antibody staining kit (BD, 556028) according to manufacturer´s conditions. Images were either acquired on a Leica TCS-SP5 confocal microscope using a 63 × 1.4 NA oil UV objective (HCX PLAPO CS) or on an Olympus FV1000 Fluoview confocal microscope using a 60 × 1.2 NA water objective (UPlanSApo). Images were collected using single excitation for each wavelength separately and dependent on secondary antibodies, and the same laser intensity settings and exposure times were used for image acquisitions of individual experiments to be quantified. Around 13–16 image sections of selected areas were acquired with a step size of 0.5 μm, and maximum intensity projections of z-stack images analyzed and processed using Leica Applied Systems (LAS AF6000) image acquisition software or ImageJ. Only cells which displayed clear centrosomal staining were analyzed and in all cases, mitotic cells as determined by DAPI staining were excluded from the analysis. For both LCLs and PBMCs, 150–200 cells were quantified per sample, with nuclear diameter additionally determined for PBMC preparations. Sample processing and quantifications were performed blind to conditions. Some experimental conditions were independently quantified by an additional two observers blind to condition and at distinct research sites (Rutgers and Lille), with identical results obtained in all cases. Upon completion of all experiments, the patient code was unveiled for subsequent data analysis. Quantification of the percentage of cells displaying pT73-Rab10 staining was performed over non-processed and non-saturated images acquired during the same time with the same laser intensities. LCL cell clumps were dispersed by pipetting, and 1 × 106 cells were treated in 1.5 ml tubes with 1 mM LLOMe (Sigma, L7393) or with DMSO or 50 nM MLi2 for 2 h at 37 °C. Cells were centrifuged at 120 × g for 5 min at room temperature, resuspended gently in 1 ml PBS and then pelleted again. The cell pellet was resuspended in 100 μl PBS containing protease/phosphatase inhibitors and 1× SDS sample buffer. Samples were briefly sonicated three times, centrifuged for 10 min at 4 °C, and the supernatant boiled at 95 °C for 5 min. Alternatively, the cell pellet was resuspended in 100 μl freshly-prepared lysis buffer 50 mM Tris-HCl pH 7.5, 1% (v/v) Triton X 100, 1 mM EGTA, 1 mM Na3VO4, 50 mM NaF, 10 mM beta-glycerophosphate, 5 mM sodium pyrophosphate, 0.27 M sucrose, 0.1% (v/v) beta-mercaptoethanol, 1× cOmplete (EDTA-free) protease inhibitor cocktail (Roche, 04-693-124-001), 1 μg/ml Microcystin-LR (Enzo Life Sciences, Cat# number ALX-350-012-M001) and snap-frozen in liquid N2 and stored at -80 °C. Protein concentration was estimated using the BCA assay (Pierce) according to manufacturer´s specifications. Extracts were mixed with SDS sample buffer supplemented with beta-mercaptoethanol (final volume 2.5% v/v) and heated at 95 °C for 5 min. Ten to fifteen micrograms of samples were loaded onto 4–20% precast polyacrylamide gels (Bio-Rad, 456-1096) and electrophoresed at 60 V (stacking) and 80 V (separating) in SDS running buffer (Tris-Glycine Running Buffer; 25 mM TRIS pH 8.6, 190 mM glycine, 0.1% SDS). Proteins were transferred to nitrocellulose membranes using the semi-dry Trans-Blot Turbo Transfer System (Biorad) for 10 min at constant 20 V (2.5 limit A). Membranes were blocked in 50% TBS (20 mM Tris-HCl, pH 7.6, 150 mM NaCl) containing 50% of blocking buffer (Li-COR Biosciences, Intercept blocking buffer (TBS), 927-60001) for 1 h at room temperature, followed by crop** into three pieces for Li-COR multiplexing (top piece until 75 kD, middle piece until 37 kD, bottom piece). Membranes were incubated with primary antibodies in 50% TBST (TBS containing 0.1% (v/v) Tween-20) in 50% of Li-COR blocking buffer overnight at 4 °C. The top piece was incubated with a rabbit anti-S935-LRRK2 antibody (1:500, Abcam, ab133450) multiplexed with a mouse monoclonal anti-LRRK2 antibody (1:1000, Antibodies Inc, 75-235). The middle piece was incubated with a mouse monoclonal anti-α-tubulin antibody (1:10´000, Sigma, clone DM1A), and the bottom piece was incubated with a rabbit monoclonal anti-pT73-Rab10 antibody (1:1000, Abcam, ab230261) multiplexed with a mouse monoclonal total Rab10 antibody (1:1000, Sigma, SAB5300028). Determination of Rab12 and phospho-Rab12 levels was performed from parallel membranes with either a rabbit monoclonal anti-pS106-Rab12 antibody (1:1000, Abcam, ab256487) or a rabbit polyclonal total Rab12 antibody (1:500, ProteinTech, 18843-1-AP). Membranes were washed three times for 10 min in 0.1% Tween-20/PBS, followed by incubation with secondary antibodies for 1 h at room temperature in 50% TBST in 50% Li-COR blocking buffer. Secondary antibodies included goat anti-rabbit IRDye 800CW and goat anti-mouse IRDye 680RD (1:10´000). Membranes were washed with 0.1% Tween-20/PBS for three times 10 min each. Blots were imaged via near-infrared fluorescent detection using Odyssey CLx imaging system, and quantification was performed using the instrument´s Image Studio software. For each LCL line, fresh extracts from 2–3 independent cultures were analyzed, and representative immunoblots are shown in the figures, with all immunoblots depicted in supplementary figures. All sample processing and quantifications were performed blind to conditions. Upon completion of all experiments, the patient code was unveiled for subsequent data analysis. All individual blots derive from the same experiment and were processed in parallel. Whole exome sequencing (WES, Macrogen Korea) and long-range PCR and Sanger sequencing of the GBA gene were performed as previously described58,88. To identify potential genes/genetic variants that may mediate the MLi2-sensitive cohesion response, we examined the burden of rare (popmax AF < 0.0001 from gnomAD non-neuro population) mutations within subjects WES data. Both indels and SNVs were included in the analysis (multi-allelics were separated and indels were left-aligned). Variants previously identified within the ReFiNE full blacklist (0.01) were filtered. Only non-synonymous variants with functional refGene annotation in “splicing”, “exonic” or “exonic/splicing” were included. Gene burden analysis was performed using TRAPD89 on all variants passing filters between TSS and TES. The UniProt (Apr 2020 hg38 release) of protein domain annotations were used for protein domain burden analysis. Rare variants were found within a total of 18,394 unique protein domains annotated to 4232 genes of which each were tested. For each gene/protein domain, a dominant and recessive test was performed. A dominant test uses cases with one or more variants within the gene of interest, whereas a recessive test uses 2 or more variants. The results from the burden test are summarized within Supplementary Tables 2–3. Note that none of the p-values pass false discovery rate correction (p < 0.05, Benjamini & Hochberg). Gene ontology was performed on genes with a p-value < 0.05 (uncorrected) from each model using PANTHER. For pathway analysis, the autosomal dominant model/protein domains gene list was scanned for over-representation of KEGG pathways (http://www.webgestalt.org/) and also using the String Site (https://string-db.org/cgi/input?sessionId=bYAdyBStPoNM&input_page_show_search=on). Data were checked for normal distribution using the Shapiro-Wilk test. One-way ANOVA with Tukey´s post-hoc test was employed, with significance set at p < 0.05. All p-values are indicated in the legends to figures. Spearman correlations were used to determine associations between protein levels and/or splitting values. Paired t-test analysis was performed for comparison of the splitting phenotypes in the presence versus absence of MLi2. All statistical analyses and graphs employed the use of Prism software version 9.5 (GraphPad, San Diego, CA). Further information on research design is available in the Nature Research Reporting Summary linked to this article.Cell culture and treatments
Immunocytochemistry
Image acquisition and analysis
Cell extracts and Western blotting
Sequencing and data analysis
Statistical analysis
Reporting summary
Data availability
The de-identified genetic data (whole exome sequence variant call file (VCF)) and their associated phenotype data (MLi2-sensitive cohesion phenotype) are available in Zenodo (DOI 10.5281/zenodo.1027821). Raw Western blot data are available as supplemental figures, and all raw images of cohesion determinations are available upon request.
References
Cheng, H. C., Ulane, C. M. & Burke, R. E. Clinical progression in Parkinson disease and the neurobiology of axons. Ann. Neurol. 67, 715–725 (2010).
Marras, C. & Lang, A. Parkinson’s disease subtypes: lost in translation? J. Neurol. Neurosurg. Psychiatry 84, 409–415 (2013).
Mestre, T. A. et al. Parkinson’s disease subtypes: critical appraisal and recommendations. J. Parkinsons Dis. 11, 395–404 (2021).
Healy, D. G. et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet Neurol. 7, 583–590 (2008).
Nalls, M. A. et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat. Genet. 46, 989–993 (2014).
Simon-Sanchez, J. et al. Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat. Genet. 41, 1308–1312 (2009).
Sharma, M. et al. Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology 79, 659–667 (2012).
Kluss, J. H., Mamais, A. & Cookson, M. R. LRRK2 links genetic and sporadic Parkinson’s disease. Biochem. Soc. Trans. 47, 651–661 (2019).
Steger, M. et al. Phosphoproteomics reveals that Parkinson’s disease kinase LRRK2 regulates a subset of Rab GTPases. Elife https://doi.org/10.7554/eLife.12813 (2016).
Sheng, Z. et al. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci. Transl. Med. 4, 164ra161 (2012).
Mir, R. et al. The Parkinson’s disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human. Biochem. J. 475, 1861–1883 (2018).
Di Maio, R. et al. LRRK2 activation in idiopathic Parkinson’s disease. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aar5429 (2018).
Fernandez, B. et al. Evaluation of current methods to detect cellular leucine-rich repeat kinase 2 (LRRK2) kinase activity. J. Parkinsons Dis. 12, 1423–1447 (2022).
Wallings, R. L., Herrick, M. K. & Tansey, M. G. LRRK2 at the interface between peripheral and central immune function in Parkinson’s. Front. Neurosci. 14, 443 (2020).
Kluss, J. H. et al. Detection of endogenous S1292 LRRK2 autophosphorylation in mouse tissue as a readout for kinase activity. NPJ Parkinsons Dis. 4, 13 (2018).
Steger, M. et al. Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis. Elife https://doi.org/10.7554/eLife.31012 (2017).
Pfeffer, S. R. Rab GTPases: master regulators of membrane trafficking. Curr. Opin. Cell Biol. 6, 522–526 (1994).
Rideout, H. J. et al. The current state-of-the art of LRRK2-based biomarker assay development in Parkinson’s disease. Front. Neurosci. 14, 865 (2020).
Fan, Y. et al. Interrogating Parkinson’s disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils. Biochem. J. 475, 23–44 (2018).
Atashrazm, F. et al. LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson’s disease patients. Mov. Disord. 34, 406–415 (2019).
Nirujogi, R. S. et al. Development of a multiplexed targeted mass spectrometry assay for LRRK2-phosphorylated Rabs and Ser910/Ser935 biomarker sites. Biochem. J. 478, 299–326 (2021).
Fan, Y. et al. R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils. Acta Neuropathol. 142, 475–494 (2021).
Karayel, O. et al. Accurate MS-based Rab10 phosphorylation stoichiometry determination as readout for LRRK2 activity in Parkinson’s disease. Mol. Cell. Proteomics 19, 1546–1560 (2020).
Padmanabhan, S. et al. An assessment of LRRK2 serine 935 phosphorylation in human peripheral blood mononuclear cells in idiopathic Parkinson’s disease and G2019S LRRK2 cohorts. J. Parkinsons Dis. 10, 623–629 (2020).
Wang, X. et al. Understanding LRRK2 kinase activity in preclinical models and human subjects through quantitative analysis of LRRK2 and pT73 Rab10. Sci. Rep. 11, 12900 (2021).
Wallings, R. L. et al. WHOPPA enables parallel assessment of leucine-rich repeat kinase 2 and glucocerebrosidase enzymatic activity in Parkinson’s disease monocytes. Front. Cell. Neurosci. 16, 892899 (2022).
Petropoulou-Vathi, L. et al. Distinct profiles of LRRK2 activation and Rab GTPase phosphorylation in clinical samples from different PD cohorts. NPJ Parkinsons Dis. 8, 73 (2022).
Melachroinou, K. et al. Elevated in vitro kinase activity in peripheral blood mononuclear cells of leucine-rich repeat kinase 2 G2019S carriers: a novel enzyme-linked immunosorbent assay-based method. Mov. Disord. 35, 2095–2100 (2020).
Bonet-Ponce, L. & Cookson, M. R. LRRK2 recruitment, activity, and function in organelles. FEBS J. 289, 6871–6890 (2022).
Alcalay, R. N. et al. Higher urine bis(Monoacylglycerol)phosphate levels in LRRK2 G2019S mutation carriers: implications for therapeutic development. Mov. Disord. 35, 134–141 (2020).
Jennings, D. et al. Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease. Sci. Transl. Med. 14, eabj2658 (2022).
Jennings, D. et al. LRRK2 inhibition by BIIB122 in healthy participants and patients with Parkinson’s disease. Mov. Disord. 38, 386–398 (2023).
Fraser, K. B. et al. Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson’s disease. Mov. Disord. 31, 1543–1550 (2016).
Fraser, K. B., Moehle, M. S., Alcalay, R. N., West, A. B. & Consortium, L. C. Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers. Neurology 86, 994–999 (2016).
Wang, S., Kelly, K., Brotchie, J. M., Koprich, J. B. & West, A. B. Exosome markers of LRRK2 kinase inhibition. NPJ Parkinsons Dis. 6, 32 (2020).
Taymans, J. M. et al. Alterations in the LRRK2-Rab pathway in urinary extracellular vesicles as Parkinson’s disease and pharmacodynamic biomarkers. NPJ Parkinsons Dis. 9, 21 (2023).
Virreira Winter, S. et al. Urinary proteome profiling for stratifying patients with familial Parkinson’s disease. EMBO Mol. Med. 13, e13257 (2021).
Rivero-Rios, P. et al. The G2019S variant of leucine-rich repeat kinase 2 (LRRK2) alters endolysosomal trafficking by impairing the function of the GTPase RAB8A. J. Biol. Chem. 294, 4738–4758 (2019).
Rivero-Rios, P., Romo-Lozano, M., Fernandez, B., Fdez, E. & Hilfiker, S. Distinct Roles for RAB10 and RAB29 in Pathogenic LRRK2-Mediated Endolysosomal Trafficking Alterations. Cells https://doi.org/10.3390/cells9071719 (2020).
Dhekne, H. S. et al. A pathway for Parkinson’s Disease LRRK2 kinase to block primary cilia and Sonic hedgehog signaling in the brain. Elife https://doi.org/10.7554/eLife.40202 (2018).
Lara Ordonez, A. J. et al. The LRRK2 signaling network converges on a centriolar phospho-Rab10/RILPL1 complex to cause deficits in centrosome cohesion and cell polarization. Biol. Open https://doi.org/10.1242/bio.059468 (2022).
Fdez, E. et al. Pathogenic LRRK2 regulates centrosome cohesion via Rab10/RILPL1-mediated CDK5RAP2 displacement. iScience 25, 104476 (2022).
Lara Ordonez, A. J. et al. RAB8, RAB10 and RILPL1 contribute to both LRRK2 kinase-mediated centrosomal cohesion and ciliogenesis deficits. Hum. Mol. Genet. 28, 3552–3568 (2019).
Khan, S. S. et al. Pathogenic LRRK2 control of primary cilia and Hedgehog signaling in neurons and astrocytes of mouse brain. Elife https://doi.org/10.7554/eLife.67900 (2021).
Barrera, J. A. et al. CDK5RAP2 regulates centriole engagement and cohesion in mice. Dev. Cell 18, 913–926 (2010).
Graser, S., Stierhof, Y. D. & Nigg, E. A. Cep68 and Cep215 (Cdk5rap2) are required for centrosome cohesion. J. Cell Sci. 120, 4321–4331 (2007).
Mayor, T., Stierhof, Y. D., Tanaka, K., Fry, A. M. & Nigg, E. A. The centrosomal protein C-Nap1 is required for cell cycle-regulated centrosome cohesion. J. Cell Biol. 151, 837–846 (2000).
Mahen, R. cNap1 bridges centriole contact sites to maintain centrosome cohesion. PLoS Biol. 20, e3001854 (2022).
Hannaford, M. R. et al. Pericentrin interacts with Kinesin-1 to drive centriole motility. J. Cell Biol. https://doi.org/10.1083/jcb.202112097 (2022).
Dang, H. & Schiebel, E. Emerging roles of centrosome cohesion. Open Biol. 12, 220229 (2022).
Madero-Perez, J. et al. Parkinson disease-associated mutations in LRRK2 cause centrosomal defects via Rab8a phosphorylation. Mol. Neurodegener. 13, 3 (2018).
Fernandez, B. et al. Centrosomal cohesion deficits as cellular biomarker in lymphoblastoid cell lines from LRRK2 Parkinson’s disease patients. Biochem. J. 476, 2797–2813 (2019).
Bonet-Ponce, L. et al. LRRK2 mediates tubulation and vesicle sorting from lysosomes. Sci. Adv. https://doi.org/10.1126/sciadv.abb2454 (2020).
Herbst, S. et al. LRRK2 activation controls the repair of damaged endomembranes in macrophages. EMBO J. 39, e104494 (2020).
Kalogeropulou, A. F. et al. Endogenous Rab29 does not impact basal or stimulated LRRK2 pathway activity. Biochem. J. 477, 4397–4423 (2020).
Lautier, C. et al. Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. Am. J. Hum. Genet. 82, 822–833 (2008).
Saini, P. et al. Association study of DNAJC13, UCHL1, HTRA2, GIGYF2, and EIF4G1 with Parkinson’s disease. Neurobiol. Aging 100, 119 e117–119 e113 (2021).
Lesage, S. et al. Large-scale screening of the Gaucher’s disease-related glucocerebrosidase gene in Europeans with Parkinson’s disease. Hum. Mol. Genet. 20, 202–210 (2011).
Wainszelbaum, M. J. et al. The hominoid-specific oncogene TBC1D3 activates Ras and modulates epidermal growth factor receptor signaling and trafficking. J. Biol. Chem. 283, 13233–13242 (2008).
Shi, C. H. et al. NOTCH2NLC intermediate-length repeat expansions are associated with Parkinson disease. Ann. Neurol. 89, 182–187 (2021).
Liu, P. et al. The role of NOTCH2NLC in Parkinson’s disease: a clinical, neuroimaging, and pathological study. Eur. J. Neurol. 29, 1610–1618 (2022).
Popesco, M. C. et al. Human lineage-specific amplification, selection, and neuronal expression of DUF1220 domains. Science 313, 1304–1307 (2006).
Fiddes, I. T., Pollen, A. A., Davis, J. M. & Sikela, J. M. Paired involvement of human-specific Olduvai domains and NOTCH2NL genes in human brain evolution. Hum. Genet. 138, 715–721 (2019).
Ju, X. C. et al. The hominoid-specific gene TBC1D3 promotes generation of basal neural progenitors and induces cortical folding in mice. Elife https://doi.org/10.7554/eLife.18197 (2016).
Hou, Q. Q., **ao, Q., Sun, X. Y., Ju, X. C. & Luo, Z. G. TBC1D3 promotes neural progenitor proliferation by suppressing the histone methyltransferase G9a. Sci. Adv. https://doi.org/10.1126/sciadv.aba8053 (2021).
Suzuki, I. K. et al. Human-specific NOTCH2NL genes expand cortical neurogenesis through delta/notch regulation. Cell 173, 1370–1384 e1316 (2018).
Keeney, J. G. et al. DUF1220 protein domains drive proliferation in human neural stem cells and are associated with increased cortical volume in anthropoid primates. Brain Struct. Funct. 220, 3053–3060 (2015).
Fdez, E. et al. Protocol to measure centrosome cohesion deficits mediated by pathogenic LRRK2 in cultured cells using confocal microscopy. STAR Protoc. 4, 102024 (2023).
Autissier, P., Soulas, C., Burdo, T. H. & Williams, K. C. Evaluation of a 12-color flow cytometry panel to study lymphocyte, monocyte, and dendritic cell subsets in humans. Cytometry A 77, 410–419 (2010).
Kluss, J. H. et al. Preclinical modeling of chronic inhibition of the Parkinson’s disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo. Mol. Neurodegener. 16, 17 (2021).
Kluss, J. H. et al. Lysosomal positioning regulates Rab10 phosphorylation at LRRK2. Proc. Natl. Acad. Sci. USA 119, e2205492119 (2022).
Verde, I. et al. Myomegalin is a novel protein of the Golgi/centrosome that interacts with a cyclic nucleotide phosphodiesterase. J. Biol. Chem. 276, 11189–11198 (2001).
Roubin, R. et al. Myomegalin is necessary for the formation of centrosomal and Golgi-derived microtubules. Biol. Open 2, 238–250 (2013).
Peng, H. et al. Myomegalin regulates Hedgehog pathway by controlling PDE4D at the centrosome. Mol. Biol. Cell 32, 1807–1817 (2021).
Watanabe, K., Takao, D., Ito, K. K., Takahashi, M. & Kitagawa, D. The Cep57-pericentrin module organizes PCM expansion and centriole engagement. Nat. Commun. 10, 931 (2019).
Kluss, J. H., Bonet-Ponce, L., Lewis, P. A. & Cookson, M. R. Directing LRRK2 to membranes of the endolysosomal pathway triggers RAB phosphorylation and JIP4 recruitment. Neurobiol. Dis. 170, 105769 (2022).
Boecker, C. A., Goldsmith, J., Dou, D., Cajka, G. G. & Holzbaur, E. L. F. Increased LRRK2 kinase activity alters neuronal autophagy by disrupting the axonal transport of autophagosomes. Curr. Biol. 31, 2140–2154 e2146 (2021).
Douanne, T., Stinchcombe, J. C. & Griffiths, G. M. Teasing out function from morphology: Similarities between primary cilia and immune synapses. J. Cell Biol. https://doi.org/10.1083/jcb.202102089 (2021).
Delecluse, H. J., Bartnizke, S., Hammerschmidt, W., Bullerdiek, J. & Bornkamm, G. W. Episomal and integrated copies of Epstein-Barr virus coexist in Burkitt lymphoma cell lines. J. Virol. 67, 1292–1299 (1993).
Tzellos, S. & Farrell, P. J. Epstein-barr virus sequence variation-biology and disease. Pathogens 1, 156–174 (2012).
Gonzalez-Hunt, C. P. et al. Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson’s disease. Sci. Rep. 10, 17293 (2020).
Howlett, E. H. et al. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson’s disease. Hum. Mol. Genet. 26, 4340–4351 (2017).
Qi, R. et al. A blood-based marker of mitochondrial DNA damage in Parkinson’s disease. Sci. Transl. Med. 15, eabo1557 (2023).
Sanders, L. H. et al. LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson’s disease patients: reversal by gene correction. Neurobiol. Dis. 62, 381–386 (2014).
Kozina, E., Byrne, M. & Smeyne, R. J. Mutant LRRK2 in lymphocytes regulates neurodegeneration via IL-6 in an inflammatory model of Parkinson’s disease. NPJ Parkinsons Dis. 8, 24 (2022).
Louie, L. G. & King, M. C. A novel approach to establishing permanent lymphoblastoid cell lines: Epstein-Barr virus transformation of cryopreserved lymphocytes. Am. J. Hum. Genet. 48, 637–638 (1991).
Kedariti, M. et al. LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease. NPJ Parkinsons Dis. 8, 92 (2022).
Dobson-Stone, C. et al. CYLD is a causative gene for frontotemporal dementia - amyotrophic lateral sclerosis. Brain 143, 783–799 (2020).
Guo, M. H., Plummer, L., Chan, Y. M., Hirschhorn, J. N. & Lippincott, M. F. Burden testing of rare variants identified through exome sequencing via publicly available control data. Am. J. Hum. Genet. 103, 522–534 (2018).
Acknowledgements
We thank all patients and their families for donating blood samples, which made this study possible. We thank Laura Montosa, Besma Brahmia and Rollanda Bernadin for help with image acquisition, and Laurine Vandevinkel and Claire Deldycke for their help with cell culture. This work was funded by grants from the Michael J. Fox Foundation for Parkinson´s Research (MJFF-019358: SH, MCCH, JRM); (MJFF-020338: ND). The PBMC Collection at Columbia University was funded by the Michael J. Fox Foundation (RNA).
Author information
Authors and Affiliations
Contributions
Conceptualization: S.H., M.C.C.H., J.R.M. Methodology: S.H., M.C.C.H, J.R.M. Investigation: Y.N., B.F., R.F., E.F., I.C., C.L., J.B.K., E.M., A.D., J.M.T., R.N.A., N.D., G.H., Y.B., A.V., C.C. Visualization: S.H., J.B.K., N.D. Funding acquisition: S.H., M.C.C.H., J.R.M., N.D., R.A. Project administration: S.H. Supervision: S.H., M.C.C.H., J.R.M., N.D. Writing – original draft: S.H. Writing – review and editing: Y.N., B.F., R.F., E.F., I.C., C.L., J.B.K., E.M., A.D., J.M.T., S.P., M.D., R.A., N.D., G.H., J.R.M., M.C.C.H., S.H.
Corresponding author
Ethics declarations
Competing interests
N.D. is Associate Editor of npj Parkinson´s Disease. N.D. was not involved in the journal´s review of, or decisions related to, this manuscript. The remaining authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Naaldijk, Y., Fernández, B., Fasiczka, R. et al. A potential patient stratification biomarker for Parkinson´s disease based on LRRK2 kinase-mediated centrosomal alterations in peripheral blood-derived cells. npj Parkinsons Dis. 10, 12 (2024). https://doi.org/10.1038/s41531-023-00624-8
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41531-023-00624-8
- Springer Nature Limited